David A. Siegel Vbi Vaccines Inc Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.38 - $22.5 $31,312 - $1.85 Million	-82,400 Reduced 40.29%	122,100 $47,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $23.4 $131,619 - $4.22 Million	-180,300 Reduced 46.86%	204,500 $144,000
Q2 2022 Aug 15, 2022	SELL	$0.66 - $1.81 $50,820 - $139,370	-77,000 Reduced 16.67%	384,800 $311,000
Q1 2022 May 16, 2022	BUY	$1.27 - $2.47 $188,468 - $366,548	148,400 Added 47.35%	461,800 $767,000
Q4 2021 Feb 14, 2022	BUY	$2.21 - $3.22 $692,614 - $1.01 Million	313,400 New	313,400 $733,000
Q1 2021 May 17, 2021	SELL	$2.91 - $4.32 $65,475 - $97,200	-22,500 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.15 - $3.5 $994,375 - $1.62 Million	-462,500 Reduced 95.36%	22,500 $62,000
Q3 2020 Nov 16, 2020	BUY	$2.77 - $6.17 $679,204 - $1.51 Million	245,200 Added 102.25%	485,000 $1.39 Million
Q2 2020 Aug 14, 2020	BUY	$0.87 - $3.13 $208,626 - $750,574	239,800 New	239,800 $743,000
Q1 2020 May 15, 2020	SELL	$0.73 - $1.91 $18,177 - $47,559	-24,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.48 - $1.38 $11,952 - $34,362	24,900 New	24,900 $34,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.